Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody is a phase 2, interventional study registered as NCT06014944 by Changhai Hospital, with a registry enrolment figure of 30 participants, started 2023-09-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody. Conditions listed: Rectal Cancer. Primary outcome: cCR rate. Colorectal eligibility wording from the registry: "Age 18-75 years old ( including 18 and 75 years old ) ; rectal adenocarcinoma was histologically confirmed as pMMR / MSS type ( according to the detection criteria of the institutional testing center, it can be detected by immunohistochemistry, PCR or NGS ), and was staged as stage II ( T3-4N0 ) or ". No results are recorded here; the registry entry is the source.